HBN-1 Hibernaid In the News

Contact us for more information

Acute sepsis kills approximately 120,000- 200,000 people annually in the United States. It is the second leading cause of death in non-coronary ICU patients. Overall, sepsis is the tenth most common cause of death in the United States and accounts for as much as 25% of ICU bed utilization. Overall mortality is in the range of 40-44%, but rates rise to between 70-90% when sepsis proceeds to severe septicemia, which is characterized by organ dysfunction, hypotension or hypo-perfusion, and septic shock, which is severe sepsis with hypotension, despite adequate fluid resuscitation.

Septic shock is becoming increasingly common in the North American population because of increasing population at risk including elderly individuals many of whom have chronic debilitating disease, and increasing numbers of people with impaired immunity due to diseases, such as cancer and AIDS. About 750,000 cases of sepsis occur each year in the United States and newer treatment approaches are desperately needed since no truly effective, curative treatments exist.

“Sepsis Suite”

Hibernaid is developing a “suite” of products to address severe sepsis and septic shock, each with a different therapeutic target and mechanism of action, and together comprising a multifocal grouping of synergistic products.  

  • A drug program that addresses the basic physiology of septic shock
  • A drug program that utilizes pharmacologically-induced thermoregulation to address organ preservation and neuroprotection
  • A medical device that addresses elimination/reduction of bacteria

HBN Medical Device
Hibernaid is engineering an extracorporeal blood disinfection device that employs intense violet range (IVR) light that selectively reduces or kills pathogens in human blood, including the most common causative organisms associated with sepsis:

  • Gram-positive bacteria- 52.9%
  • Gram-negative bacteria- 41.6%
  • Anaerobic organisms- 1.4%
  • Fungi- 4.1%, including Candida albicans
  • Gram-negatives: Proteus, Serratia, Pseudomonas aeruginosa, Neisseria meningitudis, Escherichia coli Klebsiella pneumoniae
  • Gram-positives: Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pyogenes, Streptococcus pneumoniae, enterococci

This new technology will dramatically reduce sepsis-induced death. The company is currently collaborating on a development program with the Center for Nanotechnology & Engineering (CNSE) at the University of Albany in New York.

HBN-1
Based on recent published evidence suggesting that hypothermia may be effective in the treatment of sepsis, Hibernaid’s lead compound, HBN-1 will soon be evaluated in a sepsis animal model.

HBN-3 and HBN-4

Hibernaid is in the process of acquiring two novel compounds for the treatment of septic shock. Based on a comprehensive preclinical program, these compounds work by interrupting various aspects of the causative cascade of events responsible for the progression of sepsis to septic shock.